Treatment of Adolescents With Type I Gaucher Disease Using LY-M001 Injection

A Prospective, Single-center, Open-arm, Single-arm Clinical Study to Evaluate the Safety and Efficacy of a Single Intravenous Infusion of LY-M001 Injection in Adolescents With Type I Gaucher Disease

This study is testing a new injection for adolescents with Type I Gaucher Disease to see if it is safe and effective for them.

Quick facts

• Phase: EARLY_PHASE1
• Study type: Interventional
• Enrollment: 9 (estimated)
• Ages: 12 Years to 18 Years
• Sex: All
• Sponsor: Shanghai Jiao Tong University School of Medicine (other)
• Locations: 1 site (Shanghai, Shanghai)
• Trial ID: NCT06528080 on ClinicalTrials.gov

What this trial studies

This clinical study evaluates the safety, tolerability, efficacy, immunogenicity, pharmacodynamics, and pharmacokinetics of LY-M001 injection in adolescents aged 12 to 18 years with Type I Gaucher Disease. The study plans to enroll 6-9 patients over a period of 5 years, including a main study phase lasting 52 weeks and a long-term follow-up phase extending from 53 weeks to 5 years post-treatment. Participants will be assigned to different dose groups, with safety assessments conducted after the initial dose before proceeding to higher doses. The study is open-label and involves multiple follow-up visits to monitor patient outcomes.

Who should consider this trial

Good fit: Ideal candidates are adolescents aged 12 to 18 years with confirmed Type I Gaucher Disease and specific genetic mutations.

Not a fit: Patients outside the age range or those without the specific genetic mutations associated with Type I Gaucher Disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for adolescents suffering from Type I Gaucher Disease.

How similar studies have performed: While this approach is novel, similar studies have shown promise in treating Gaucher Disease with gene therapy techniques.

Eligibility criteria

Inclusion Criteria:

1. The subject and/or parent, caregiver, or legal representative must be willing and able to provide written informed consent/consent for the study in accordance with applicable regulations and guidelines and comply with all study access and procedures, including the use of any data collection devices that can be used to directly record participant data;
2. Gender is not limited, 12 years old ≤ 18 years old;
3. Patients with double allele mutation of glucocerebrosidase gene (GBA1) and decreased glucocerebrosidase activity were confirmed by laboratory tests and met the clinical manifestations of type I Gaucher disease;
4. Subjects were newly treated or treated patients with type I Gaucher disease; For patients treated with enzyme replacement therapy (ERT) or substrate clearance therapy (SRT) before screening, 5 drug half-lives are required before administration;
5. The subject is willing to participate in all study follow-up and comply with all study procedures and evaluations;
6. The subject must be willing to refrain from donating blood, organs, tissues, or cells at any time after receiving treatment;
7. Pregnant Women (WOCBP) subjects tested negative for pregnancy. Note: WOCBP is defined as a female subject who has not achieved postmenopausal status (continuous amenorrhea for at least 12 months with no clear cause other than menopause) after menstruating, and who has no surgical (i.e., bilateral ovariectomy, fallopian tube removal, and/or hysterectomy) or other investigator identified cause of permanent infertility (e.g., mallear tube agenesis).

Exclusion Criteria:

1. Positive AAV8 neutralizing antibody (antibody titer \> 1:10).
2. Patients with type II or III Gaucher disease (GD2 or GD3), or with suspected Gaucher disease as assessed by the investigator (e.g., subjects with Gaucher disease-related central nervous system manifestations or abnormal electroencephalogram \[EEG\] examination).
3. Active and progressive bone diseases that are expected to require surgical treatment within the next 6 months.
4. The subjects were judged by the investigator to have idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), thrombocytopenia, anemia, hepatomeglia, splenomeglia, and/or osteoporosis unrelated to GD (bone mineral density z-score ±2).
5. Treatment with an investigational drug in another clinical study within 28 days prior to screening or 5 half-lives, whichever is older.
6. Evidence of a history of clinically significant liver disease or hepatotoxin exposure that meets, but is not limited to, any of the following at the time of screening:

   ① Progressive hepatomegaly larger than 3 times the normal volume

   ② History of stage 2 or above hepatic fibrosis

   ③AST, ALT, or TBIL were 1.5 times higher than the upper limit of normal (ULN)

   ④ Immune hepatitis Hepatitis B surface antigen (HBsAg) positive, and hepatitis B virus deoxyribonucleic acid (HBV-DNA) positive (HBV-DNA\>103 copy number /mL); Or take hepatitis B drugs (such as interferon, lamivudine, adefovir and entecavir); Or hepatitis C virus (HCV) antibody positive.
7. The subject's blood indicators have any of the following:

   ① The hemoglobin value was \<8.0 g/dL

   ② Platelet count \<40 × 109/L
8. Refractory epilepsy.
9. Human immunodeficiency virus (HIV) antibody positive or treponema syphilis antibody positive.
10. Subjects had significant clinical comorbidities (such as malignant tumors, primary biliary cirrhosis, or autoimmune liver disease) that the investigators believed might affect the study data or confounding the findings.
11. Subjects have received or plan to receive bone marrow transplantation, hematopoietic stem cell transplantation, and/or major organ transplantation, including but not limited to liver transplantation, kidney transplantation, etc.
12. 3 months before screening, subjects received treatment with erythropoietin, whole blood transfusion, or red blood cell transfusion; Or received platelet transfusion 1 month before screening.
13. Allergic to any component of LY-M001 injection.
14. Previous treatment with any type of gene therapy or cell therapy.
15. Use of systemic immunosuppressant or steroid therapy within 3 months prior to administration (other than immunosuppressive therapy prescribed for prophylactic administration).
16. Any condition in which the subject is unable to undergo magnetic resonance imaging (MRI) studies (including hypersensitivity to anesthetics or contrast agents).
17. Have received live attenuated vaccine within 4 months prior to screening or plan to receive live attenuated vaccine during clinical trials.
18. Other situations in which the investigator considers the subject inappropriate for study participation.

Where this trial is running

Shanghai, Shanghai

• Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University — Shanghai, Shanghai, China (RECRUITING)

Study contacts

• Study coordinator: xiumin wang, PhD

Conditions: Gaucher Disease